Raab & Moskowitz Asset Management LLC Sells 212 Shares of AbbVie Inc. (NYSE:ABBV)

Raab & Moskowitz Asset Management LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 0.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,302 shares of the company’s stock after selling 212 shares during the quarter. AbbVie makes up approximately 1.1% of Raab & Moskowitz Asset Management LLC’s holdings, making the stock its 22nd biggest holding. Raab & Moskowitz Asset Management LLC’s holdings in AbbVie were worth $4,674,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the business. AMF Tjanstepension AB acquired a new position in shares of AbbVie during the 3rd quarter worth about $8,777,000. Creative Planning grew its holdings in AbbVie by 5.8% during the third quarter. Creative Planning now owns 750,811 shares of the company’s stock valued at $147,086,000 after purchasing an additional 40,925 shares during the period. Swedbank AB increased its stake in AbbVie by 0.3% in the third quarter. Swedbank AB now owns 2,147,126 shares of the company’s stock valued at $424,014,000 after purchasing an additional 6,810 shares in the last quarter. Luts & Greenleigh Group Inc. raised its holdings in AbbVie by 1.0% in the third quarter. Luts & Greenleigh Group Inc. now owns 13,757 shares of the company’s stock worth $2,717,000 after purchasing an additional 131 shares during the period. Finally, Magnus Financial Group LLC boosted its position in shares of AbbVie by 10.2% during the third quarter. Magnus Financial Group LLC now owns 8,978 shares of the company’s stock worth $1,773,000 after purchasing an additional 829 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on ABBV shares. Raymond James restated an “outperform” rating and issued a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Piper Sandler increased their price target on AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Daiwa Capital Markets cut AbbVie from an “outperform” rating to a “neutral” rating and set a $180.00 price objective on the stock. in a report on Thursday, December 5th. Wells Fargo & Company boosted their price objective on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Leerink Partners upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price on the stock in a report on Friday, November 22nd. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

Insider Transactions at AbbVie

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.25% of the stock is owned by corporate insiders.

AbbVie Price Performance

Shares of NYSE ABBV opened at $193.06 on Thursday. AbbVie Inc. has a fifty-two week low of $153.58 and a fifty-two week high of $207.32. The company has a debt-to-equity ratio of 9.64, a current ratio of 0.65 and a quick ratio of 0.54. The business has a 50-day moving average of $177.91 and a 200-day moving average of $185.86. The stock has a market capitalization of $341.16 billion, a price-to-earnings ratio of 80.44, a PEG ratio of 1.53 and a beta of 0.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 257.91%. During the same period last year, the firm earned $2.79 earnings per share. As a group, sell-side analysts predict that AbbVie Inc. will post 12.32 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.